Abstract: Background: In the management of non-ST-elevation acute coronary syndrome (NST-ACS) a gap between guideline-recommended care and actual practice has been reported. A systematic overview of the actual extent of this gap, its potential impact on patient-outcomes, and influential factors is lacking.
INTRODUCTION
Non-ST-Elevation Acute Coronary Syndromes (NST-ACS) comprise one of the most common types of ACS, encompassing the two sub-conditions Unstable Angina (UA) and Non-ST-Elevation Myocardial Infarction (NSTEMI). The proportion of patients diagnosed with these conditions has increased substantially in the past two decades, whereas the proportion of ST-Elevation Myocardial Infarction (STEMI) patients has decreased [1] . In addition, NST-ACS patients have a higher long-term risk of myocardial infarction and/or death as compared with STEMI patients [2] [3] [4] [5] . In various studies indicating that a substantial proportion of NST-ACS patients does not receive care according to the guidelines [12, 13] . Up until now, only two literature reviews reported on potential guideline-practice gaps in the management of ACS patients. One review summarized literature on guideline adherence in ACS patients in general [14] , whereas the second focused on adherence in the management of NST-ACS patients specifically [15] . This latter review, however, only included studies from a single registry (i.e., CRU-SADE) conducted primarily in the USA. In addition, previous research concluded that the extent of adherence to clinical guidelines can be influenced by factors related to the patient, the health care provider or the organization [16] [17] [18] . Several studies showed a wide variety of factors that were associated with (under)utilization of evidence-based therapies, but an overview of potential factors associated with guideline adherence in NST-ACS patients is lacking. Given that in a previous study low guideline adherence in NST-ACS patients was associated with adverse cardiac events, such as death and myocardial infarction (MI) [19] , and NST-ACS prevalence rates are increasing [20] , insight in the extent of guideline adherence, potential practice gaps and the impact on patient outcomes in this specific patient group is necessary. The results can be used to stress the importance of optimizing clinical management among policy-makers and clinicians. The aims of the current systematic literature review were to 1) examine the extent of adherence to international cardiac guideline recommendations, 2) study the association between guideline adherence and adverse cardiac events (i.e., death and/or MI), and 3) identify potential factors associated with guideline adherence in the management of patients with NST-ACS.
METHODS
A systematic review of the literature was conducted. In reporting the results of this study, the "Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA)" statement was used [21] .
Search Strategy
A literature search was conducted in PUBMED (including MEDLINE), EMBASE, CINAHL, and the Cochrane library until March 2016. The search strategies were constructed in cooperation with an information specialist from the library of the VU University Amsterdam and included search terms related to adherence combined with terms related to guidelines or protocols, MI, and UA (Appendix A). No restrictions were applied. In addition to the electronic search, reference lists of the included studies were manually screened for additional relevant articles. When the full-text of a study was not available online, either the first author was approached to request a copy of the study or a full-text copy was ordered online. The Cochrane database for systematic reviews was searched for systematic literature reviews on adherence in NST-ACS care, but none were found.
Selection of Studies
Two reviewers (JE, ND) independently screened all studies identified in the initial search on title and abstract. Studies were selected for full-text screening if guideline adherence in NST-ACS patients was addressed in either the title or abstract. In case of disagreement between the reviewers, a third reviewer was consulted (IvdW). Subsequently, two reviewers (JE, ND) screened the full-text of these selected studies independently. Studies that met all of the following criteria were included in this systematic literature review: a. The study focused on adherence in NST-ACS patients to either the American College of Cardiology (ACC/AHA) or the European Society of Cardiology (ESC) guidelines (versions developed since 2000);
b. The study reported on one or more of the following guideline recommendations: acute in-hospital pharmacological treatment, risk stratification to decide on the need for early invasive procedures (i.e. electrocardiogram (ECG), troponin assessment, or use of validated risk scores), performance of in-hospital CA in intermediate to high risk patients, and/or the prescription of discharge medications (Box 1);
c. The study sample included adults (≥18 years) with NST-ACS (i.e., UA and/or NSTEMI);
d. The study design was observational or (quasi-) experimental;
e. The study was conducted in a hospital setting.
Studies were excluded from this systematic literature review when:
a. Adherence to ACC/AHA and/or ESC guideline recommendations was studied in a subgroup of NST-ACS patients (e.g., NST-ACS patients with diabetes mellitus);
b. The study design was not observational or (quasi-) experimental (e.g., review, editorial, letter to the editor, opinion paper, conference abstract, qualitative study, or design article).
Methodological quality assessments
The methodological quality of the included studies was assessed by two reviewers independently (JE, ND), using a checklist based on the STROBE statement for observational studies [22] . The checklist comprised 11 items: title and abstract, introduction and objectives, study design, participant selection and sample size, variables, data sources and methods, data analyses, participant flow, descriptive data, main results, and discussion. Each item on the checklist was scored 0 in case an adequate description of the item in the paper was lacking or not reported, 0.5 in case an adequate description was given but minimal data were reported, or 1 in case both were adequate. Scores on the 11 items were summed and as a result, each study received a total score that ranged from 0 (poor study quality) to 11 (excellent study quality). Scores between 0-6 reflected poor study quality, scores >6 -<8 reflected moderate study quality, scores ≥8 -<10 reflected good study quality and scores ≥10 reflected excellent study quality. Agreement between the reviewers was considered substantial: in 87 % of the assessed studies quality scores of both reviewers did not differ more than 0.5 point and there were no studies of which the scores of both reviewers differed more than one point.
Data extraction
Data of the included studies were extracted by one reviewer (JE) and thoroughly checked by a second reviewer (ND). Using a standardized data extraction form, the following characteristics were extracted: first author, year of publication, country of data collection, study design, data collection methods, study sample, type of guideline(s) evaluated (i.e., ACC/AHA and/or ESC), type of recommendation(s) evaluated, and main results.
In the data extraction process, the following criteria were applied:
• When included studies focused on the management of both STEMI and NST-ACS patients, only the results for NST-ACS patients were extracted;
• When data of the included studies were collected at different time points (e.g., cohort studies), only details of the latest measurement were reported as these provided the most recent information; Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin II AT1 receptor blockers; CA, coronary angiography; ECG, electrocardiogram; GRACE, global registry of acute coronary events. †class of recommendation: class I refers to the condition in which there is evidence or general agreement that a certain procedure or treatment is beneficial, useful, effective, and thus recommended/should be performed; class II refers to the condition in which there is conflicting evidence about the usefulness or efficacy of a certain procedure or treatment, and thus should (class IIa) or may (class IIb) be considered. class III refers to the condition in which there is evidence or general agreement that a certain procedure or treatment is not useful or effective, and even in some cases be harmful, and is thus not recommended. †Level of evidence: Level A refers to data derived from multiple randomized clinical trials or meta-analyses; Level B refers to data derived from a single randomized clinical trial or large non-randomized studies; Level C refers to consensus of opinion of the experts and/or small studies, retrospective studies or registries. ‡In eligible patients according to the guidelines. ∞ Guideline update.
• When studies had a pretest-posttest design in which the effect of an intervention was assessed, only details from the pretest measurement were extracted, as we did not aim to evaluate intervention effects;
• Of the studies focusing on potential factors associated with guideline adherence, only the statistically significant associations from multivariable analyses were extracted (p ≤ 0.05).
RESULTS

Description of the studies
The final selection of studies consisted of 45 studies (Fig.  1) . Of the included studies, 21 studies were conducted in the USA [12, 13, 19, [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] , 12 in Europe [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] , four in Canada [53] [54] [55] [56] , five in Asia [57] [58] [59] [60] [61] , two in New-Zealand [62, 63] , and one study was conducted in multiple countries [64] . The majority of studies had an observational study design, with the exception of three studies who respectively concerned a pilot study [52] , a descriptive study [61] , and a before-after study [47] . Sample sizes of the included studies ranged from 121 to 2,515,106 patient admissions. Two studies were single-center studies [58, 63] , while the other studies were multicenter studies.
Methodological Quality
The methodological quality assessment indicated that the quality of 36 included studies was excellent or good [12, 13, 19, 23-25, 27-38, 40, 41, 44, 45, 47, 48, 50-60, 64] , whereas the quality of seven studies was scored moderate [26, 42, 46, 49, 61, 62, 63] and two studies were scored poor [39, 43] ( Table 1) . Most studies lacked a detailed description of primary and secondary outcomes and related measurement sources, the handling of missing data, and/or the adjustment for confounders in multivariable analyses. With regard to the description of the study design, the majority of studies referred to a previously reported design paper.
Main Results
Results were categorized into (1) the extent of adherence to ACC/AHA and/or ESC guideline recommendations; (2) the association between guideline adherence and adverse cardiac events (i.e., death and/or MI); and/or (3) potential factors associated with guideline adherence. Given that guideline recommendations were overall comparable, in this categorization no distinction between the ACC/AHA and ESC guidelines was made. Also different versions of both guidelines, published over the years, were highly comparable in class and level of evidence (Box 1).
The Extent of Adherence to Cardiac Guideline Recommendations
Acute in-Hospital Pharmacological Treatment
Thirty-four studies reported on the extent of adherence to guideline recommendations on acute in-hospital pharmacological treatment, including the prescription of aspirin, betablockers, platelet aggregation inhibitors (e.g., clopidogrel), glycoprotein IIb/IIIa inhibitors, and/or heparin [12, 13, 19, 23, 25, 26, 28, 29, 31-38, 40-46, 48, 49, 51-54, 59-63] . Overall, adherence rates in these studies varied from 0.5% [61] to 98.3% [60] . The three lowest adherence rates were related to recommendations regarding the early prescription of glycoprotein IIb/IIIa inhibitors (0.5 % [61] , 0.6 % [62] , and 1.8 % [59] , whereas the three highest adherence rates were related to recommendations on the early prescription of aspirin (97.0 % [41] , 97.1 % [13] , and 98.3% [60] ) ( Table 2) .
Risk Stratification
Six studies reported on guideline adherence regarding risk stratification to decide on the need for early invasive procedures [25, 27, 43, 47, 50, 61] . Adherence rates of 34.3 % [27], 35.6 % [25] , and 82.0 % [47] for the performance of an ECG within 10 min after arrival at the hospital were reported. In addition, two studies, one with poor and another with moderate methodological quality, indicated that in respectively 92.0 % and 93.0 % of NST-ACS patients troponin assessment was used as a risk stratification method [43, 61] . One study reported on the use of validated risk-scoring instruments in practice, such as the Global Registry of Acute Coronary Events (GRACE) or the Thrombolysis In Myocardial Infarction (TIMI) risk scores. In 57% of NST-ACS patients a validated risk score outcome was documented in their medical chart, with scores ranging between hospitals from 16.7 % to 87.0 % [50] . 65.8 % [25] CA was performed inhospital within 48 h after admission. In four studies CAadherence rates were stratified by patients' risk status, with results being mixed. In three of these studies high-risk patients were less likely to receive in-hospital CA as compared with low-risk patients [38, 55, 56] , while in one study 25 .0 % of low-risk patients received in-hospital CA versus 56.0 % of high-risk patients [43] (Table 3) . However, methodological quality of this latter study was scored poor ( Table 1) . Methodological quality was assessed using a checklist based on the STROBE criteria, consisting of 11 items. Items were scored as following: 1 = described, ½ = partly described, 0 = not/insufficiently described. Total score ranged from 0-11, where scores between 0 -6 reflected poor study quality, >6 -<8 moderate study quality, ≥8 -<10 good study quality and ≥10 excellent study quality. 
Performing in-Hospital
Discharge Medications
Twenty-three studies reported on guideline adherence with regard to recommended discharge medications, including angiotensin-converting-enzyme (ACE) inhibitors /angiotensin II AT 1 receptor blockers (ARBs), aspirin, betablockers, platelet aggregation inhibitors (e.g., clopidogrel), and/or statins [12, 13, 19, 23, 26, 30, 31, 33, 34, 36, 38, 40-44, 46, 49, 51, 57, 58, 62, 64] . Overall, adherence rates in these studies varied from 4.2 % [58] to 97.3 % [13] . The three lowest adherence rates were related to recommendations regarding the prescription of ARBs (4.2 %) [58] , clopidogrel (9.5 % for NSTEMI and 5.1 % for UA) [62] , and aspirin (16.0 %) [57] at discharge. Hence, all three studies had relatively small sample sizes (ranging from 380-1,331). Although in the majority of studies low adherence rates were reported for the prescription of clopidogrel at discharge (<59.0 %), in six studies adherence rates were found ranging from 67.0 % to 90.8 % [13, 23, 31, 40, 51, 58] . The study with the highest adherence score, however, concerned a single center study with a small sample size (n=380).
The three highest adherence rates were related to recommendations regarding the prescription of aspirin (96.0 % [41] and 97.3 % [13] , respectively) and beta-blockers (97.0 % [13] ) at discharge. Overall, adherence rates for the prescription of aspirin at discharge were higher than 90.0 %, but in one study only 16.0 % of NST-ACS patients were prescribed this type of medication at discharge [57] . However, combined with the administration of clopidogrel 61.8 % also received aspirin ( Table 2) .
Association Between Guideline Adherence and Adverse Cardiac Events
Seven of the included studies reported on the association between guideline adherence and occurrence of adverse cardiac events (i.e., death and/or MI) in NST-ACS patients [19, 24, 28, 29, 32, 45, 55] (Table 4) . Overall, in all studies, higher adherence to guideline recommendations was significantly associated with a lower occurrence of death or the composite endpoint of death/MI. For example, patients who received early treatment with glycoprotein IIb/IIIa inhibitors [28] or underwent in-hospital CA [24] had lower mortality rates than patients who did not receive such therapies. Mixed results were found for the association between guideline adherence and the occurrence of myocardial infarction (MI). In one study higher guideline adherence was associated with lower rates of MI [29] , whereas in two studies higher guideline adherence was associated with higher rates of MI [32, 55] . In two other studies, no significant association between guideline adherence and MI was found [24, 28] .
Potential Factors Associated with Guideline Adherence
Fifteen of the included studies examined potential factors that were associated with lower or higher guideline adherence [19, 24, 25, 28-30, 32, 34, 37, 49, 50, 53, 56, 57, 64] (Fig. 2, Table 5 ). Of these, eight studies reported on factors associated with adherence to guideline recommendations on acute in-hospital pharmacological treatment [19, 25, 28, 29, 32, 34, 53, 56] . In addition, four studies reported on potential factors influencing adherence to the performance of inhospital CA [24, 37, 49, 56] , whereas seven studies reported on potential factors related to the prescription of discharge medications [19, 28, 30, 34, 56, 57, 64] . One study reported on potential factors associated with adherence to recommendations on risk stratification [50] . Overall, these factors could be categorized in either patient-related or organizationrelated factors.
Acute in-Hospital Pharmacological Treatment
The following patient-related factors were associated with higher prescription rates of acute in-hospital pharmacological treatment: white race [28, 32] , hypercholesterolemia [28, 29] , (recent) smoker [28, 32] , hypertension [28] , family history of coronary artery disease [28, 29] , prior beta-blocker use [29] , high admission blood pressure [29] , positive cardiac markers (e.g. troponin, CK-MB, CK) [28, 34] , transient ST-elevation or ST-depression on the ECG [28, 29, 34] , and receiving CA in-hospital or within 24 h after admission [53] . On the contrary, the following patientrelated factors were related to lower prescription of acute inhospital pharmacological treatment: older age [28, 29, 32, 34] , female gender [28, 29, 32] , high admission heart rate [28, 29] , chronic heart failure [28, 29, 53] , prior stroke [28] , prior MI [28] prior CABG [28] , diabetes mellitus [34] , acute in-hospital heart failure [28, 29, 34] , kidney failure [28, 29, 34] , bleeding [53] , high GRACE risk status [53, 56] , presentation at the hospital with cardiac arrest [53] . Mixed results were found for factors prior percutaneous coronary intervention (PCI) and health-insurance, which were in some studies associated with higher prescription rates of acute inhospital pharmacological treatment [29, 32, 53] , whereas in other studies they were related to lower prescription rates [28, 29] .
On an organizational level, patients with a cardiologist as their primary care provider [19, 28, 29, 34] , patients treated at hospitals accredited by the Society of Cardiovascular Patient Accreditation (SCPC) [25] , and patients treated at hospitals with a teaching status [29] or cardiac surgery facilities (e.g., facilities for coronary artery bypass grafting (CABG) surgery) [19] were more likely to receive acute in-hospital pharmacological treatment. Patients treated at hospitals with catheterization, but no cardiac surgery, facilities were less likely to receive such treatment [53] .
Performing in-Hospital CA
Patient-related factors, including white race [24] , high admission blood pressure [24] , hypercholesterolemia [24] , (recent) smoking [24] , high body mass index [24] , positive family history of CAD [24] , prior PCI [24] , positive cardiac markers (e.g. troponin, CK-MB, CK) [24, 37, 49] , and transient ST-elevation or ST-depression on the ECG [24, 49] , were associated with higher performance rates of in-hospital CA. On the other hand, older age [24, 49] , female gender [24, 56] , high admission heart rate [24] , chronic heart failure [24] , diabetes mellitus [24, 49] , in-hospital heart failure [24] , prior stroke [24] , kidney failure [24] , high GRACE risk status [56] , prior CABG [24] , prior MI [24] , presenting in- †class I guideline recommendation: I = acute pharmacological care (<24 h after admission), II = risk stratification, III = invasive procedures, IV = discharge medications. ‡Only significant associations are presented, and where possible adjusted odds ratios (AOR) and their 95% confidence intervals (CI) are provided. §Concern large registries that provide access to quality improvement tools, e.g. quarterly feedback reports/benchmarks. ∞Pharmacotherapy index: range from 0-7, one point for each medication received, ASA, clopidogrel, GB IIa/IIIb inhibitor, LMW Heparin, BB, ACE/ARB and statin.
hospital during off-hours [24] , and having no insurance or a Medicare insurance [24] were related to lower performance rates of in-hospital CA.
On an organizational level, factors such as, patients treated at hospitals with catheterization [56] , PCI [24] , or cardiac surgery facilities [24] , patients form the Midwest/west region (USA) (geographical location) [24] and patients with a cardiologist as their primary care provider [24, 56] were more likely to receive in-hospital CA. However, patients admitted at larger size hospitals (i.e., higher number of hospital beds) [24] , and patients from Northeast region (USA) (geographical location) [24] were less likely to receive in-hospital CA. Mixed results were found on an organizational level with regard to a hospital's teaching status, with in one study this factor being associated with higher performance rates of in-hospital CA [49] , whereas in another study this factor was associated with lower CA-rates [24] .
Risk Stratification
The following patient-related factors were associated with higher cardiac risk score use: obesity and former smoker, whereas a diagnosis of unstable angina (versus NSTEMI), being resuscitated in-hospital, acute heart failure and tachycardia were associated with lower cardiac risk score use [50] .
Discharge Medications
The following patient-related factors were associated with higher prescription rates of discharge medications: white race [30] , high admission blood pressure [30] , hypercholesterolemia [30] , (recent) smoking [30] , angina pectoris [64] , peripheral artery disease [30] , prior PCI [30] , prior CABG [30] , prior MI [30, 64] , diabetes mellitus [30] , hypertension [64] , prior clopidogrel use [30, 57] , risk factors for coronary artery disease [57] , positive cardiac markers (e.g. troponin, CK-MB, CK) [30, 34] , transient ST-elevation or ST-depression on the ECG [34] , and receiving in-hospital CA [30] . On the contrary, older age [34, 64] , female gender [64] , high admission heart rate [30] , chronic heart failure [64] , high GRACE risk status [56] , diagnosis of NSTEMI [57] , prior heparin use [30] , kidney failure [34] , ejection fraction of less than 40% [30] , bleeding [30] , atrial fibrillation [64] , and in-hospital cardiogenic shock [64] were associated with lower prescription of discharge medications. Mixed results were found for in-hospital heart failure, prior stroke, and low hemoglobin levels with in some studies these factors being associated with higher prescription rates of discharge medications [57] , whereas in other studies opposite associations were found [30, 64] .
On an organizational level, NST-ACS patients treated at hospitals with cardiac surgery facilities [19] , as well as [34] and GP IIb/IIIa inhibitors [28, 32] , CA ≤48 h or in-hospital [24, 49] , statin [34] , and all guideline recommended therapies (i.e. ACE, aspirin, BB, statin) [64] [29] and GP IIb/IIIa inhibitors [28, 32] , to receive CA ≤48 h or in-hospital [24, 56] , and to receive all guideline recommended discharge therapies (i.e. ACE, aspirin, BB, statin) [64] than male patients
Patients of white race were more likely to receive acute GPIIb/IIIa inhibitors [28, 32] , CA ≤48 h [24] , and clopidogrel at discharge [30] than patients of a non-white race
Clinical factors
Angina pectoris Patients with a history of angina pectoris were more likely to receive all guideline recommended discharge therapies (i.e. ACE, aspirin, BB, statin), than patients without a history of angina pectoris [64]
↑ CHF Patients with chronic heart failure were less likely to receive acute antiplatelet therapy (e.g. clopidogrel) [53] , BB [29] and GPIIb/IIIa inhibitors [28] , to receive CA ≤48 h [24] , and all guideline recommended discharge therapies (i.e. ACE, aspirin, BB, statin) [64] , than patients without chronic heart failure [53] and GPIIb/IIIa inhibitors [32] , to receive CA ≤48 h [24] , and to receive clopidogrel at discharge [30] [28] , to receive CA ≤48 h [24] , and all guideline recommended therapies (i.e. ACE, aspirin, BB, statin) [64] at discharge, than patients without a stroke in their medical history
Patients with a prior stroke were more likely to receive clopidogrel at discharge [57] , than patients without a stroke in their medical history
Patients with a high BMI were more likely to receive CA ≤48 h [24] , and more likely to have a risk score documented in their medical chart [50] , than patients with a normal BMI ↑ ↑
Patient
CAD risk factors
Patients with two or more risk factors for CAD were more likely to receive clopidogrel at discharge, than patients with one or no risk factors for CAD [57] ↑ Guideline Adherence in the Management of NST-ACS Current Cardiology Reviews, 2017, Vol. 13, No. 1 19 ( 
Clinical factors
Diabetes mellitus
Patients with diabetes mellitus were less likely to receive acute aspirin [34] , and to receive CA ≤48 h or in-hospital [24, 49] , than patients without diabetes mellitus
Patients with diabetes mellitus were more likely to receive clopidogrel [30] and all guideline recommended therapies (i.e. ACE, aspirin, BB, statin) [64] at discharge, than patients without diabetes mellitus
Patients with an EF <40% were less likely to be prescribed with clopidogrel at discharge, than patients without an EF <40% [30] ↓
Family history of CAD
Patients with a positive family history for CAD were more likely to receive acute BB [29] and GP IIb/IIIa inhibitors [28] , and CA ≤48 h [24] than patients with a negative family history of CAD ↑ ↑ Heart failure (acute) Patients with acute heart failure were less likely to receive acute aspirin, heparin [34] , GP IIb/IIIa inhibitors [28] and BB [29, 34] , to receive CA ≤48 h [24] , and less likely to receive all guideline recommended discharge therapies (i.e. ACE, aspirin, BB, statin) [64] , than patients without acute heart failure. They were also less likely to have a risk score documented in their medical chart [50] Patients with acute heart failure were more likely to be prescribed with ACE at discharge, than patients without acute heart failure [34] ↓ ↓ ↓ ↓
↑ Hypercholesterolemia
Patients with hypercholesterolemia were more likely to receive acute BB [29] and GPIIb/IIIa inhibitors [28] , to receive CA ≤48 h [24] , and to receive clopidogrel at discharge [30] , than patients without hypercholesterolemia
Patients with a history of hypertension were more likely to receive acute GPIIb/IIIa inhibitors [28] , and to receive all guideline recommended discharge therapies (i.e. ACE, aspirin, BB, statin) [64] , than patients without a history of hypertension ↑ ↑
Kidney failure
Patients with kidney failure were less likely to receive acute aspirin, heparin [34] , BB [29] and GPIIb/IIIa inhibitors [28] , to receive CA ≤48 h [24] , and to receive aspirin and ACE at discharge [34] , than patients without kidney failure ↓ ↓ ↓ NSTEMI NSTEMI patients were less likely to receive clopidogrel at discharge than patients with UA [57] , but were more likely to have a risk score documented in their medical chart [50] ↑ ↓
Risk status (GRACE)
Patients with a high risk status are less likely to receive acute antiplatelet therapy [53] and other acute medications [56] , to receive CA, and appropriate discharge medications [56] compared to patients with a low risk status
Smoking (Recent) smokers were more likely to receive acute GPIIb/IIIa inhibitors [28, 32] , CA ≤48 h [24] , and clopidogrel at discharge [30] , than non-smokers (Recent) smokers were also more likely to have a risk score documented in their medical chart than non-smokers [50] ↑ ↑ ↑ ↑
Bleeding
Patients with a major bleeding in their medical history were less likely to be treated with antiplatelet therapy (e.g. clopidogrel) [53] or to receive clopidogrel at discharge [30] , than patients without a major bleeding ↓ ↓
Hemodynamics
Blood pressure
Patients with a high blood pressure at admission were more likely to receive acute BB [29] , CA ≤48 h [24] , and clopidogrel at discharge [30] than patients with a normal blood pressure at admission
Heart rate Patients with a high heart rate were less likely to receive acute BB [29] and GP IIb/IIIa inhibitors [28] , to receive CA ≤48 h [24] , and to receive clopidogrel at discharge [30] than patients with a normal heart rate at admission. They were also less likely to have a risk score documented in their medical chart [50] ↓ ↓ ↓ ↓
Cardiac arrest / resuscitation
Patients presenting with cardiac arrest or who were resuscitated at hospital-admission were less likely to be treated with acute antiplatelet therapy (e.g. clopidogrel) [53] , and less likely to have a risk score documented in their medical chart [50] , than patients not presenting with cardiac arrest or being resuscitated in hospital 
Laboratory results
Cardiac markers (e.g. troponin, CK-MB, CK)
Patients with positive cardiac markers were more likely to receive acute aspirin, BB, heparin [34] and GP IIb/IIIa inhibitors [28] , to receive CA ≤48 h or in-hospital [24, 37, 49] , and ACE, aspirin, BB, Statin [34] , clopidogrel at discharge [30] than patients with normal cardiac markers levels
Patients with HB levels of 9g/dL or lower were either less likely to receive clopidogrel at discharge [30] or more likely to receive clopidogrel at discharge [57] than patients with normal HB levels ↑ ↓
Electrocardiogram findings
Transient ST elevation
Patients with transient ST elevation were more likely to receive acute aspirin [34] , BB [29, 34] and heparin [34] , to receive CA ≤48 h [24] , and to be discharged with aspirin, BB and ACE [34] than patients without such deviations on the electrocardiogram ↑ ↑ ↑
ST depression
Patients with ST depression were more likely to receive acute aspirin [34] , BB [29, 34] , heparin [34] and GP IIb/IIIa inhibitors [28] , and to receive CA ≤48 h or inhospital [24, 49] and to be discharged with ACE, aspirin, and BB [34] [53] , and to receive clopidogrel at discharge [30] than patients not receiving CA in-hospital ↑ ↑
Other
Insurance
Patients with medicare or no insurance were less likely to receive acute BB [29] and GP IIb/IIIa inhibitors [28, 32] , and to receive CA ≤48 h than patients with private insurance [24] Patients with self-insurance were more likely to receive acute BB [29] , but less likely to receive acute GP IIb/IIIa inhibitors [28] [24] , and be among centers with the highest adherence rates regarding acute and discharge therapies [19] than patients treated at hospitals without surgical facilities
Catheterization facilities
Patients admitted to hospitals with onsite catheterization facilities were less likely to be treated with antiplatelet therapy (e.g. clopidogrel), than patients admitted to hospitals without such facilities [53] Patients admitted to hospitals with onsite catheterization facilities were more likely to receive CA, than patients treated in hospitals without such facilities [56] ↓ ↑
Organization
Cardiology care
Patients cared for by cardiologists were more likely to receive acute aspirin [34] , BB [29, 34] , heparin [34] and GP IIb/IIIa inhibitors [28] , to receive CA ≤48 h or inhospital [24, 56] , and ACE, aspirin, BB, statin at discharge [34] , and to be among centers with the highest adherence rates regarding acute and discharge therapies [19] , than patients treated by other specialists patients with a cardiologist as their primary care provider [19, 34] were more likely to receive recommended discharge medications, whereas patients admitted to hospitals with lower quality measures on MI-care [30] were less likely to receive guideline recommended pharmacological discharge care. Regarding the factor geographical location, the extent of adherence depended on the type of country where treatment was provided [64] .
All Guideline Recommendations
The following patient-related factors were associated with higher adherence to three or more guideline recommendations: white race, high blood pressure, hypercholesterolemia, (recent) smoker, positive cardiac markers (e.g. troponin, CK-MB, CK), transient ST elevation or ST depression on the electrocardiogram. On the contrary, elder age, female gender, high heart rate, chronic or acute heart failure, kidney failure, high GRACE risk status, were related to lower guideline adherence. On an organizational level, the presence of cardiac surgery facilities (e.g. CABG) and having a cardiologist as the primary care provider were associated with higher guideline adherence.
DISCUSSION
This systematic literature review examined the extent of adherence to ACC/AHA and ESC guideline recommendations on acute in-hospital pharmacological treatment, risk stratification, performing in-hospital CA, and the prescription of discharge medications in the management of NST-ACS patients. In addition, associations between guideline adherence and adverse cardiac events were examined and potential factors associated with lower or higher guideline adherence were identified.
Results of this systematic literature review showed a wide variation in guideline adherence rates to various cardiac recommendations, possibly reflecting a guideline-practice gap in the management of NST-ACS patients. Adherence rates for pharmacological therapies at admission or at discharge ranged from less than 5.0 % to more than 95.0 %, whereas adherence rates for the performance of in-hospital CA ranged between 16.0 % and 95.8 %, and between 34.3 % and 93.0 % for risk stratification. In addition, although the number of studies reporting on the association between adherence and adverse cardiac events was relatively small, lower guideline adherence was consistently found to be associated with poorer prognosis (i.e. higher rates of death, and the composite endpoint of death/MI). Finally, several patient-related (e.g. age, gender, presence of co-morbidities) and organization-related factors (e.g. teaching hospital, availability of PCI/CABG facilities) possibly influencing the extent of adherence to different guideline recommendations were identified.
The results of the current systematic literature review corroborate the findings of a previous literature review, in which suboptimal guideline adherence in the management of NST-ACS was demonstrated, with overall 25.0 % of patients not receiving appropriate pharmacological treatment [15] . Our findings also confirm results of studies on guideline adherence in other cardiac patient groups. For example, the wide variation in adherence rates found in this systematic review is in line with previous studies in STEMI patients. In some of these studies rates of 0.0 % to 2.0 % were indicated for adherence to guideline recommendations on pharmacological treatment [65, 66] , whereas in other studies rates of 98.5 % or even higher were reported [13] . In addition, this wide variation in adherence rates has been demonstrated before in a systematic review comparing guideline adherence between patients with different diseases, including cardiovascular disease, in the pre-hospital and emergency care setting [67] . Overall, adherence to various medical guidelines ranged from 0.0 % to 98.0 % in this study, with the lowest rates found for adherence to recommendations of cardiac guidelines.
Previous studies mentioned several potential reasons for this practice variation, which should be taken into account in the interpretation of our results. First, the majority of included studies concerned registries in which information on guideline adherence was derived from patients' medical records. This way, specific contra-indications providing a legit reason to deviate from the guidelines might be overlooked, as it is known that contra-indications are not always properly documented by attending physicians [68] . Consequently, guideline adherence rates reflected in these studies might be an underestimation of actual adherence rates in clinical practice. Second, it was suggested that physicians sometimes deviate from the guidelines because of inconclusive or insufficient evidence underlying guideline recommendations [16, 69] . In this review, low adherence rates were found for the early prescription of glycoprotein IIa/IIIb inhibitors and the early and discharge prescription of clopidogrel. However, at the time of publication of the majority of these studies these pharmacological therapies were relatively new, and therefore probably not yet routinely prescribed. Third, it has been shown that physicians sometimes deviate from the guidelines because of calculated complication risks. For example, cardiologists could argue that it would be better not to perform CA in high-risk patients, because of the risk of bleeding associated with this treatment. However, this kind of decisionmaking is in contrast with the guidelines, which state that especially high-risk patients should receive guidelinerecommended therapies [10, 11] .
Although over the past years there has been growing evidence regarding the effectiveness of risk stratification methods to guide clinical decision-making for the appropriate treatment, in this literature review only a minority of studies reported on this topic. Of these, three studies reported on the use of ECG findings for risk stratification and two studies reported on the use of troponin assessment. These latter studies were however of poor and moderate methodological quality, so results should be interpreted with caution. In addition, only one of the included studies reported on the use of validated risk-scoring instruments (i.e., GRACE and TIMI risk scores). The lack of studies on this topic could be explained by the fact that the use of these validated risk-scoring instruments in clinical decision making is a relatively new concept, which is mainly highlighted in the latest versions of the ACC/AHA and ESC guidelines. To further examine the actual use of validated risk scoring instruments and other risk stratification methods in clinical practice, and their effects on the quality of care, further research is needed.
Consistent with previous studies in MI and heart failure patients [70] [71] [72] [73] , in this systematic literature review lower guideline adherence was associated with adverse cardiac outcomes, including higher rates of mortality and death/MI. However, the association between adherence and the composite endpoint of death/MI should be interpreted with caution, as it has been reported before that the magnitude of the effect can differ across different components of a composite endpoint [74] [75] [76] [77] . In other words, given that mixed results were found with regard to the association between guideline adherence and MI, the association between lower guideline adherence and higher rates of death/MI seems to be mainly driven by an impact of adherence on mortality rather than infarction. Furthermore, although all the included studies on the relationship between adherence and clinical outcomes had a prospective design, the causality of this relationship needs further investigation. One could argue that it could also be the case that severe progressing symptoms -a poorer prognosis -motivates healthcare professionals to deviate from the guidelines and apply career-based, rather than evidence-based procedures.
In this systematic review a distinction could be made between factors associated with specific guideline recommendations and factors associated with recommendations on all guideline recommendations. In previous studies, in addition to patient-and organization-related factors which were found in this systematic review, also health care providerrelated factors were identified as potential associates of guideline adherence. For example, cardiologists' awareness, familiarity, and personal agreement with guidelines and its recommendations have been linked to the extent of adherence to clinical practice guidelines, as well as high workload and accessibility of the guideline [16] . Furthermore, in a study on potential reasons for non-adherence in patients with ischemic heart disease, it was indicated that the inability of guidelines to directly manage the care of individual patients could be a reason for cardiologists to deviate from guideline recommendations [78] . Given that in our review results on the association between patient-and organization-related factors and guideline adherence were mixed and information on health care provider-related factors was lacking, future research focusing on the influence of patient-, organization-, as well as provider-related factors on guideline adherence in NST-ACS patients is warranted.
Given the large variation in adherence rates and lower guideline adherence being associated with adverse clinical outcomes in several studies, close monitoring of the extent of adherence to the latest ACC/AHA and ESC guidelines for NST-ACS is essential to maintain a high standard of care in this patient group [10, 11] . Previously, several quality improvement programs have been developed, aimed to fasten implementation of cardiac guidelines in clinical practice and increase adherence rates [71, 79, 80] . However, these programs often targeted the entire population of either ACS or NST-ACS patients, rather than focusing on NST-ACS pa-tients in which treatment according to the guidelines have proven to be less likely. Two previous studies in ACS patients evaluated quality improvement initiatives in which implementation strategies were tailored to individual patient characteristics. These studies showed substantial improvements in adherence rates [81, 82] . Hence, knowledge on potential patient-, organization-, and provider-related factors influencing guideline adherence in NST-ACS could contribute to the identification of high-risk patients and the development of tailored implementation strategies aimed to increase adherence in this specific patient group [17, 83] . Additionally, previous quality improvement programs often focused on implementation of the guideline as a whole, rather than the improvement of adherence to specific guideline recommendations. It is suggested, however, that the latter more tailored approach is possibly more successful in improving adherence, as the current review and also previous studies show that adherence varies largely across individual recommendations [84] .
Study limitations
In interpreting the results of this systematic literature review, several limitations should be taken into account. First, due to heterogeneity in study design (e.g., observational versus quasi-experimental, study sample (i.e., NST-ACS, NSTEMI, and/or UA patients), and type of guideline recommendations under study, a meta-analysis was not feasible. Generalizability of study results might therefore be hampered. In addition, study quality scores of the included studies ranged from poor to excellent, which could have distorted the interpretation of study results. However, the impact of these differences is expected to be limited, as the wide variation in adherence rates was prevalent in all different types of studies, including both poor and excellent quality studies.
A second limitation of the current literature review was that the majority of included studies derived their data from patients' medical charts, which may incorporate a high risk of bias.
A third limitation is that only a few of the included studies reported on the latest versions of the ACC/AHA and ESC guidelines, published respectively in 2014 [11] and 2015 [10] . However, guideline recommendations described in the most recent versions of the guidelines are comparable to recommendations in the earlier versions of the ESC and ACC/AHA guidelines included in this review, except for the prescription of glycoprotein IIb/IIIa inhibitors, which degraded from a class 1 recommendation to a class II recommendation in both guidelines. It is recommended that future studies take the newest guidelines into account when studying the extent of adherence in the management of NST-ACS patients, and for instance explore any trends in guideline adherence.
The final limitation concerns the assessment of the methodological quality of the eligible studies by using a checklist based on the STROBE criteria. The STROBE is developed to assist authors in reporting their researcher, rather than assessing study quality. As a consequence bias can be introduced, with the methodological quality reported in this review being an overestimation or underestimation of the actual study quality. However, reliable and generally accepted tools to assess the quality of observational studies are lacking [85] .
CONCLUSION
Despite NST-ACS being one of the most common types of ACS demanding urgent and guideline-recommended care, results of this systematic literature review indicated that there seems to exist a practice gap in the management of NST-ACS, with a substantial proportion of patients not receiving guideline-recommended care. Consequently, lower adherence might be associated with a higher risk for poor prognosis. Future research should further investigate the complex nature of guideline adherence in this patient group, its impact on clinical care, and potential patient-, organization-, and provider-related factors influencing adherence. This knowledge is essential to optimize clinical management of NST-ACS patients and could guide future quality improvement initiatives. 
LIST OF ABBREVIATIONS
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